Medical Morbidity and Mortality in Schizophrenia: Guidelines for Psychiatrists
The DOI matches its Crossref record.
Abstract
BACKGROUND: Medical morbidity and mortality rates remain elevated in schizophrenia patients compared with the general population, in part due to potentially reversible medical risk factors. Psychiatrists should address this problem by adopting established strategies for prevention and intervention. METHOD: The literature on modifiable medical risk factors relevant to individuals with schizophrenia and corresponding guidelines for prevention and treatment established by expert consensus panels were reviewed. RESULTS: Schizophrenia patients are at elevated risk for cardiovascular disease due to high rates of cigarette smoking and, increasingly, due to obesity, diabetes, and hypertriglyceridemia. Rates of human immunodeficiency virus infection and infectious hepatitis are also higher in schizophrenia patients. Interventions that have reduced medical morbidity in the general population can be adopted to reduce premature mortality in individuals with schizophrenia. CONCLUSIONS: Patients with schizophrenia have high rates of potentially reversible medical morbidity. Implementation of practice guidelines for identifying and modifying risk factors could substantially improve the health of patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30078-0 · Cited by 1,304
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Goff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528
Self-citationNicotine use in schizophrenia: The self medication hypotheses
Kumari, V., & Postma, P. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.02.006 · Cited by 468
Endocrine and Metabolic Adverse Effects of Psychotropic Medications in Children and Adolescents
CORRELL, C. U., & CARLSON, H. E. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000220851.94392.30 · Cited by 403
Kane, J. M., Sanchez, R., Perry, P. P., Jin, N., Johnson, B. R., Forbes, R. A., McQuade, R. D., Carson, W. H., & Fleischhacker, W. W. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07530 · Cited by 361
Zhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia
Lencz, T., Morgan, T. V., Athanasiou, M., Dain, B., Reed, C. R., Kane, J. M., Kucherlapati, R., & Malhotra, A. K. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001983 · Cited by 278
Auquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1325 · Cited by 249
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Evins, A. E., Cather, C., Culhane, M. A., Birnbaum, A., Horowitz, J., Hsieh, E., Freudenreich, O., Henderson, D. C., Schoenfeld, D. A., Rigotti, N. A., et al. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0b013e3180ca86fa · Cited by 179
“3 – 7 Age-adjusted mortality from smokingrelated pulmonary and cardiovascular disease is 2 to 6 times higher among schizophrenic patients compared with agematched samples.(8,9) Bupropion or single preparation NRT added to CBT are well tolerated by schizophrenia patients but only modestly effective.”
BackgroundSelf-citationCompton, M. T., Daumit, G. L., & Druss, B. G. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600889256 · Cited by 177
Cigarette smoking and mortality risk in people with schizophrenia
Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., Warren, K. R., Feldman, S., Shim, J.-C., Love, R. C., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp152 · Cited by 158
Insomnia is frequent in schizophrenia and associated with night eating and obesity
Palmese, L. B., DeGeorge, P. C., Ratliff, J. C., Srihari, V. H., Wexler, B. E., Krystal, A. D., & Tek, C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.030 · Cited by 138
Medical comorbidity in patients with schizophrenia and alcohol dependence
Batki, S. L., Meszaros, Z. S., Strutynski, K., Dimmock, J. A., Leontieva, L., Ploutz-Snyder, R., Canfield, K., & Drayer, R. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.016 · Cited by 72
“There are high rates of diabetes (Dixon et al., 1999; Muir-Cochrane, 2006), hyperlipidemia, obesity (Goff et al., 2005), chronic obstructive pulmonary disease, cardiovascular disease (notably hypertension) (McCreadie, 2003), hepatitis, andHIV infection.”
Mortality in schizophrenia: clinical and serological predictors
Dickerson, F., Stallings, C., Origoni, A., Schroeder, J., Khushalani, S., & Yolken, R. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt113 · Cited by 50
Brown, R. A., Minami, H., Hecht, J., Kahler, C. W., Price, L. H., Kjome, K. L., Bloom, E. L., Levy, D. E., Carpenter, K. M., Smith, A., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0707 · Cited by 26
Efficacy and safety of varenicline for smoking cessation in schizophrenia: a meta-analysis.
Ahmed, S., Virani, S., Kotapati, V. P., Bachu, R., Adnan, M., Khan, A. M., Zubair, A., Begum, G., Kumar, J., Qureshi, M., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00428 · Cited by 20
Hecht, J., Rigotti, N. A., Minami, H., Kjome, K. L., Bloom, E. L., Kahler, C. W., Price, L. H., Levy, D. E., Carpenter, K. M., & Brown, R. A. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.06.001 · Cited by 7
Metadata
- Authors
- Goff, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., Bierer, M., Duckworth, K., & Sacks, F. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-02-15
- Volume
- 66
- Issue
- 02
- Pages
- 183-194
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2026138360
- Cited by
- 311
- References
- 0
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.